An Introduction to PEPAXTO: The First Anticancer Peptide-Drug Conjugate for the Management of Multiple Myeloma in Patients Who Have Received at Least 4 Prior Lines and are Triple-Class Refractory
Date: Thursday June 24, 2021
Time: 12:00 PM ET; 9:00 AM PT
IMPORTANT: There is a 2 step registration process -
After registering on this site, you will receive a confirmation email with instructions to register with GoToWebinar to receive your logon instructions and calendar reminder.
This webinar is sponsored by: